Zhitong Finance App News, Zhongguancun (000931.SZ) issued an announcement. Shandong Huasu Pharmaceutical Co., Ltd., a subsidiary of the company, recently received the BDB “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration. This drug is used to treat essential hypertension. It is a new compound formulation containing known active ingredients, and has not been marketed at home or abroad. Its single agent has shown efficacy and safety in clinical practice, and joint use is recommended as a clinical guideline.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.